

~ Drugs in pregnancy ~

* **Thalidomide** : Teratogenic (limb deformity)

* **Corticosteroids** → ⊕ lung maturation if preterm birth is expected

- **Phenobarbital** → ⊕ bilirubin conjugation (↑ glucuronidation) → ↓ incidence of jaundice in newborns.

- **Zidovudine** → ↓ HIV transmission to fetus [3 antiretroviral agents → eliminate transmission almost entirely]

Mechanism

* **Folic acid** → ↓ **neural tube defects** (spina bifida)

* **Folic acid antagonist**, **Retinoic acid**, **Endothelin receptor blockers** (bosentan) → **Neural crest & disruption**

* **Vit A analogs** (Isotretinoin, Etretinate) → **disrupt & differentiation**.

(DES) * **Diethylstilbestrol** (sex hormones) → ↑ risk of vaginal adenocarcinoma in daughters, & hypospadias in sons, later in life. (**endocrine disruption**)

* **Oxidative stress** → irreversible damage of DNA, pr, lipids

* **Vascular disruption** → hypohyperperfusion, hypoxia, obstruction

* **Smoking** → CVS, MSS, GIT, & renal defects, preterm, Abortion...

Malformations ~

* **Thalidomide** → Phocomelia, heart defects, gut atresia (Known)

* **Penicillamine** → loose skin (K)

* **Warfarin** → Saddle nose, Retarded growth, limbs - eyes - CNS defects (K)

* **Corticosteroids** → Cleft palate, congenital cataract

* **Androgen** → Masculinisation in ♀

* **Estrogen** → Testicular atrophy in ♂

* **Stilbestrol** → Vaginal adenosis & Ca, Cervical Ca (later in life)

* **Phenytoin** → Cleft lip palate, Microcephaly, Mental retardation (K)

* **Valporate** → Neural tube defect || (K)

* **Carbamazepine** → Neural tube defect || (Suspected)

* **Folate antagonists** → Neural tube defect ||, Hydrocephalus, Cleft palate (K)

* **Aminoglycosides** → Deafness

* **Tetracycline** → Staining of bones & teeth, Thin tooth enamel, Impaired bone growth (S) especially in 2nd & 3rd trimesters

* **Ethanol** → especially in 2nd & 3rd trimesters → **Fetal Alcohol Syndrome** (CNS + facial development) affected (K)

* **Retinoids** → Hydrocephalus (K)

* **Methotrexate**

* **Cyclophosphamide**

* **Lithium**

* **Coumarins**

Adverse effects ~

* **Thiopental** → Sedation / apnea in newborn

* **Opioids** → apnea in newborn / dependence in fetus

* **Salicylates** → ↑ bleeding + delay labor causing weak placenta → less nutrients → ↓ birth weight

* **ACE ⊖** → Oligohydramnios, renal failure (K)

* **NSAIDs**

* **Factors affecting the production of congenital malformations:**

① **Dose**

② **Developmental stage**; within first 2 weeks → no malformation - peak: 2nd - 8th week

- **Blastogenesis** (day 1 → 8): exposure might kill the blastocyte

- & are **totipotent** → if damaged can be replaced

- **Embryogenesis** (2nd → 8th week)

↳ organogenesis → greatest risk

- **Fetogenesis** (> 8 weeks)

↳ CNS, eyes, external genitalia

③ **Genetic susceptibility of embryo**

④ **Status of the mother**; <18 . >35 - malnutrition - diseases...

- Some drugs have the potential to be teratogenic. (not all)
- **The baseline risk of congenital malformations is 3-6%.**
- **3%** of congenital malformations are severe.
- **<1%** of congenital malformations are due to **drugs**.
- Genetic causes are responsible for **15-25%** of cases.
- Maternal conditions and infections, and environmental factors account for **10%** of cases.
- **65-75%** of cases are **mostly idiopathic**.

- Category A:** No evidence of fetal risk and is safe to use during pregnancy.
- Category B:** Relatively safe.
- Category C:** Information about fetal risk is not available but risk can **NOT** be ruled out.
- Category D:** Positive evidence of fetal risk.
- Category X:** Definite fetal risk and the drug is contraindicated during pregnancy.

* **Factors affecting placental transfer:**

→ Physiochemical properties

→ Duration of exposure

→ Pharmacokinetics:

↳ **Lipid solubility (α) & polarity (β).**

* **Lipophilic** → **diffuse readily**

* **Highly ionized** (Tubocurarine) → **cross slowly**
↳ if high enough, measurable amount might cross.

* **Salicylate** → **Small unionized amount can cross.**

↳ **Molecular size: (β)**

* **250 - 500** ↑ **cross easily** * **Heparin & Insulin**

* **500 - 1000** ↳ **large size** → **can't cross**

* **> 1000**

↳ **pH** [mother: 7.4 - fetus: 7.3]

* **Weak base** pKa > 7.4 → **more ionized** in fetus → **ion trapping** → **higher fetal levels.**

↳ **Placental transporters**

P. glycoprotein transporter **pumps back some drugs into maternal circulation** (anti Cancer, anti HIV)

↳ **Protein binding:**

• Fetal proteins binding affinity < maternal proteins

↳ **Sulfonamides, barbiturates, phenytoin, local anesthetic agents, glyburide**

↳ **Placental & fetal drug metabolism.** ↳ **hypoglycemic agent. (although)**

* **Phenobarbital** **we only give insulin)**

↳ **oxidized by placenta**

* **Ethanol, Smoking, benzopyrenes**

↳ **formation of toxic metabolites by placenta**


* **Teratogenic drug**

↳ result in a characteristic set of malformations.

↳ Exert its effects at a particular stage of fetal development (organogenesis).

↳ Dose dependent incidence

↳ So we give the lowest effective dose, for the shortest duration possible



Note!! The risk of neonatal abnormality in the absence of any known teratogen is 3-6 %

• effective old drugs are preferable to new alternatives

↳ we have more info about.